Rabbit Recombinant Monoclonal Kappa Opioid Receptor antibody - conjugated to APC.
IgG
Rabbit
APC
Ex: 650nm, Em: 660nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.
Kappa-type opioid receptor, K-OR-1, KOR-1, MSL-1, Oprk1
Rabbit Recombinant Monoclonal Kappa Opioid Receptor antibody - conjugated to APC.
IgG
Rabbit
APC
Ex: 650nm, Em: 660nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
EPR18881
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
+4°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This supplementary information is collated from multiple sources and compiled automatically.
The Kappa Opioid Receptor also known as KOR or kappa receptors is a type of opioid receptor that plays an important role in the nervous system. It is a protein with an approximate mass of 43 kDa. This receptor mainly expresses in the human brain especially in regions involved in pain and stress responses such as the hypothalamus and thalamus. Kappa receptors are involved in modulating neurotransmitter release and can affect synaptic transmission.
Kappa opioid receptors mediate pain perception mood regulation and stress response. They form part of a larger receptor family the G-protein coupled receptors (GPCRs) which are critical in cellular signaling. Activation of these receptors can produce analgesic effects differing from other opioid receptors due to their unique mechanism of action. Kappa receptors interact with endogenous ligands called dynorphins which are peptide neurotransmitters involved in natural pain relief processes.
Kappa opioid receptors are integral to the dopaminergic and serotonergic pathways. In the dopaminergic pathway kappa receptors reduce dopamine release influencing the reward system and potentially affecting addiction behaviors. In the serotonergic pathway they modulate serotonin levels connecting to mood and anxiety regulation. These pathways also involve proteins like the mu-opioid receptor and delta-opioid receptor which along with kappa receptors form a complex regulatory network.
Kappa opioid receptors have been linked to depression and drug addiction. In depression dysfunctional kappa receptor activity may disrupt mood regulation contributing to depressive symptoms. The associated protein dynorphin plays a role in this condition by interacting with kappa receptors. In drug addiction these receptors influence the brain's reward circuits impacting addiction severity through altered dopamine signaling. Understanding kappa receptors can offer insights into new therapeutic approaches for these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com